Daptomycin (LY146032) treatment of experimental enterococcal endocarditis
about
The life and times of the EnterococcusEffects of daptomycin and vancomycin on tobramycin nephrotoxicity in ratsIn vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.Gentamicin improves the activities of daptomycin and vancomycin against Enterococcus faecalis in vitro and in an experimental foreign-body infection model.Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic modelDaptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis.Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determinationComparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.Current perspectives on glycopeptide resistance.Daptomycin.Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci.Effect of protein binding of daptomycin on MIC and antibacterial activity.Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faeciumScreening and treatment of infections caused by resistant enterococci.Therapy of enterococcal infections.Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci.In vitro synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance.In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains.Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits.Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicinPharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs.Antimicrobial susceptibility and molecular epidemiology of beta-lactamase-producing, aminoglycoside-resistant isolates of Enterococcus faecalis.Enterococcus, an emerging pathogen.Infections due to antibiotic-resistant gram-positive cocci.Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.Comparative in vitro activity of daptomycin (LY146032) and vancomycin against gram-positive cocci determined using a pharmacokinetic model.Successful treatment of Corynebacterium striatum endocarditis with daptomycin plus rifampin.Daptomycin: a novel agent for Gram-positive infections.Bactericidal activity of daptomycin against vancomycin-resistant Enterococcus faecium in an in vitro pharmacokinetic model.
P2860
Q24616875-AE98BA26-9AF1-4A4C-B529-B67C113727A7Q28330353-7FA21DFE-735E-4E9E-ABD0-C3E5315B9E52Q33979251-8CC0A456-AC09-48DD-8103-2A0E8C09474AQ35270357-68AA9250-6E50-4B30-B522-898F152DF14DQ35276965-6EBF60D9-8E23-46E1-9803-A9B2F6BD908BQ35280233-6003F47F-4354-42DC-9A53-187E0984C96CQ35285000-EDBF42F5-4FB4-4418-8FAD-B914AD47ADD5Q35332478-879EC3DD-D448-48C9-84D0-ACE8E4347CA4Q35368590-88BA869B-373D-4490-BAC5-7DD6D72F5C0AQ35637066-D546E090-F2A3-45EC-A68A-C5D03C6D0E08Q35896915-60761E68-E478-4B9E-BF5B-0DCC26B9043EQ36757414-114FC96D-B3CD-43C5-9BE6-EF9811EA10BCQ36758113-FEFD5907-C49B-4DF8-AEF4-B30241401815Q37711795-528911B5-83D6-4D1A-B55A-02853EE52CD6Q37909576-C34A1F95-BB04-4FAB-915C-DE4CD588F563Q38577676-8280E5E5-7F9D-411B-966A-F94789853005Q39818976-D35513A3-7019-4E13-B496-09C23579D8F7Q39819619-D1D33BFF-3854-4F92-9B6F-38BD28AAFD6CQ39819894-81967048-AE8E-46FE-8FA0-9584FE2599C3Q39833014-9E5BA826-1EB2-4342-992F-34B7A5380488Q40087244-FFE77E32-38F0-4F12-9F6E-1E9C34ECE266Q40284223-E0C19DD9-BE7D-48AB-B930-7DA0033B0D0DQ40785841-83F00E37-C6D6-47A0-A468-62C4292FBADAQ40804876-199AC65E-5AF3-4D7D-B0B8-E9A788C53E1FQ44579110-6AD74F69-8FFD-4C74-9F5A-BE5DBD655728Q44672108-3187FA52-A940-4DC5-B449-16B3ED96303EQ46689355-FA77DA25-D8D8-4E52-BF8B-BFC7AE5331A9Q53852746-3B11FC58-2501-4E6F-834F-C87B5574B0AFQ54284517-C3A911A5-D790-43E2-86A5-CDE3755910C6
P2860
Daptomycin (LY146032) treatment of experimental enterococcal endocarditis
description
1988 nî lūn-bûn
@nan
1988 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Daptomycin (LY146032) treatment of experimental enterococcal endocarditis
@ast
Daptomycin (LY146032) treatment of experimental enterococcal endocarditis
@en
type
label
Daptomycin (LY146032) treatment of experimental enterococcal endocarditis
@ast
Daptomycin (LY146032) treatment of experimental enterococcal endocarditis
@en
prefLabel
Daptomycin (LY146032) treatment of experimental enterococcal endocarditis
@ast
Daptomycin (LY146032) treatment of experimental enterococcal endocarditis
@en
P2093
P2860
P356
P1476
Daptomycin (LY146032) treatment of experimental enterococcal endocarditis
@en
P2093
P2860
P304
P356
10.1128/AAC.32.6.877
P407
P577
1988-06-01T00:00:00Z